Yogesh Jadhav’s Post

View profile for Yogesh Jadhav, graphic

📈 10M+ Views | 🚀 Turning Data into Actionable Insights | 🤖 AI, ML & Analytics Expert | 🎥 Content Creator & YouTuber | 💻 Power Apps Innovator | 🖼️ NFTs Advocate | 💡 Tech & Innovation Visionary | 🔔 Follow for More

New ETF, Tema Cardiovascular and Metabolic (HRTS), has been listed on Nasdaq, offering investors a chance to cash in on the Ozempic-fueled weight loss trend. The ETF contains positions in around 20 companies involved in anti-obesity and cardiovascular-related treatments, including Novo Nordisk and Eli Lilly. The popularity of thematic ETF investments has waned this year, with investors withdrawing $4.7 billion from such funds. On the other hand, GLP-1 drugs have had a significant impact on the biopharmaceutical space, with Novo Nordisk becoming Europe's largest company and Eli Lilly climbing to be among the top 10 S&P 500 companies. #ETF #Ozempic #WeightLoss #Investing

New ETF, Tema Cardiovascular and Metabolic (HRTS), has been listed on Nasdaq, offering investors a chance to cash in on the Ozempic-fueled weight loss trend. The ETF contains positions in around 20 companies involved in anti-obesity and cardiovascular-related treatments, including Novo Nordisk and Eli Lilly. The popularity of thematic ETF investments has waned this year, with investors withdr...

New ETF, Tema Cardiovascular and Metabolic (HRTS), has been listed on Nasdaq, offering investors a chance to cash in on the Ozempic-fueled weight loss trend. The ETF contains positions in around 20 companies involved in anti-obesity and cardiovascular-related treatments, including Novo Nordisk and Eli Lilly. The popularity of thematic ETF investments has waned this year, with investors withdr...

markets.businessinsider.com

To view or add a comment, sign in

Explore topics